| Cas No.: | 41332-24-5 |
| Chemical Name: | 1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one |
| Synonyms: | NP 118809,NP118809 |
| SMILES: | O=C(N1CCN(C(C2=CC=CC=C2)C3=CC=CC=C3)CC1)CC(C4=CC=CC=C4)C5=CC=CC=C5 |
| Formula: | C32H32N2O |
| M.Wt: | 460.62 |
| Purity: | >98% |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | NP118809 is a potent N-type calcium channel blocker, with an IC50 of 0.11 μM; also less potently inhibits L-type calcium channel with an IC50 of 12.2 μM. |
| Target: | N-Type Ca2+ Channel:0.11 μM (IC50) L-type calcium channel:12.2 μM (IC50) |
| In Vivo: | NP118809 (25 mg/kg, i.p.) shows significant analgesic activity in the phase IIA portions of the rat formalin model[1]. NP118809 (30 mg/kg, p.o.) results in 80.3% inhibition of mechanical allodynia and 96.3% inhibition of thermal hyperalgesia in the rat spinal nerve ligation model[2]. |
| In Vitro: | NP118809 is a potent N-type calcium channel blocker, with an IC50 of 0.11 μM; also inhibits L-type calcium channel with an IC50 of 12.2 μM. NP118809 inhibits the hERG potassium channel in HEK cells, with an IC50 of 7.4 μM[1]. |
| References: | [1]. Zamponi GW, et al. Scaffold-based design and synthesis of potent N-type calcium channel blockers. Bioorg Med Chem Lett. 2009 Nov 15;19(22):6467-72. [2]. Pajouhesh H, et al. Structure-activity relationships of diphenylpiperazine N-type calcium channel inhibitors. Bioorg Med Chem Lett. 2010 Feb 15;20(4):1378-83. |

To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
